Seeking Alpha

Amgen (AMGN) and AstraZeneca (AZN) have agreed to collaborate on the development and...

Amgen (AMGN) and AstraZeneca (AZN) have agreed to collaborate on the development and commercialization of 5 drugs in Amgen's clinical inflammation porfolio. AstraZeneca will lead the way in developing 3 of the 5 drugs.  AstraZeneca will make a $50M one-time payment to Amgen, as well as royalty payments following commercialization.
Comments (1)
  • norjud
    , contributor
    Comments (225) | Send Message
     
    wow...Amgen a good company. What's in it for them?
    2 Apr 2012, 07:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector